Filing Flows › Neuroone Medical Technologies (NMTC) › Q4 FY25
Neuroone Medical Technologies (NMTC) Q4 FY25 earnings results (fourth quarter fiscal 2025)
10-K filed Dec 17, 2025
Neuroone Medical Technologies (NMTC) reported revenue of $2.7M for the fourth quarter fiscal 2025 (Q4 FY25), +907% from a year earlier and +62% from the quarter before. Operating margin was -50.0%, net loss $1.6M (59.1% of revenue).
Neuroone Medical Technologies, Q4 FY25: revenue $2.7M (+907% year over year), operating margin -50.0%, net loss $1.6M, operating cash flow −$1.5M. The chart follows the revenue to costs, profit and cash.
| Q4 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.7M | +62% | +907% |
| Operating profit | −$1.4M | — | — |
| Net earnings | −$1.6M | — | — |
| Operating cash flow | −$1.5M | — | — |
What changed
Revenue was $2.7M in Q4 FY25, up 907% year over year and up 62% from the previous quarter.
Gross margin was 55.8%, up 4.0 points from Q4 FY24. Operating costs exceeded revenue by $1.4M, an operating margin of -50.0%. Operating expenses fell 2% while revenue rose 907%. The quarter ended with a net loss of $1.6M, wider than the previous quarter's $1.5M loss.
Operating cash flow was −$1.5M. Non-cash charges added back $64K of depreciation and amortization and $359K of share-based compensation. Working capital and other items used $329K. Capital expenditures of $11K exceeded it, leaving free cash flow of −$1.5M.
Questions
What was Neuroone Medical Technologies' revenue in the fourth quarter fiscal 2025?
Neuroone Medical Technologies (NMTC) reported revenue of $2.7M for the fourth quarter fiscal 2025 (Q4 FY25), +907% from a year earlier and +62% from the quarter before.
Was Neuroone Medical Technologies profitable in the fourth quarter fiscal 2025?
Operating loss was $1.4M (-50.0% of revenue) and net loss $1.6M.